PROGRAM BOOK 2018 Arizona United Rheumatology Alliance 2018 ANNUAL MEETING June 1 – 3, 2018 Enchantment Resort Sedona, Arizona WELCOME MESSAGE

On behalf of the Arizona United Rheumatology Alliance, I would like to welcome and thank you for attending the 2018 AURA Annual Meeting. The organization has undergone significant restructuring within the last 12 months; however, our primary goal of providing the highest quality scientific and clinical educational event in a unique and enjoyable environment has persisted. I am honored to preside over the 2018 Annual Meeting, which stands to continue the tradition of excellence that AURA has developed over the last few years.

We have a bold agenda with a diverse faculty to enlighten us on a wide range of subjects: classic rheumatic diseases such as lupus and the inflammatory myopathies; rare diseases and complications including auotinflammatory bone disorders and macrophage activation syndrome; cutting edge clinical research from “real world” data; pertinent local topics including coccidioidomycosis and rheumatic diseases; and topics of interest including the therapeutic aspects of Cannabis and potential barriers for management of rheumatic patients with pharmacy benefit managers. This year’s meeting would not be possible without the continued strong support from our industry sponsors, and I encourage you to interact with their representatives both in the exhibit hall and during our various social events throughout the weekend. Finally, I would like to thank the Board Members of AURA for their dedication and hard work helping to make this event possible. Thank you again for your participation, and please enjoy Sedona!

Sincerely,

Kaleo Ede, MD

AURA Chairman of the Board

AURA 2017-2018 BOARD OF DIRECTORS Chairman of the Board Advocacy Chair HEADQUARTER OFFICE Kaleo Ede, MD Theresa Frimel, FNP-C WJWeiser & Associates, Inc. Phoenix, AZ Scottsdale, AZ 1100 E. Woodfield Road, Suite 350 Schaumburg, IL 60173 Secretary Program Planning Committee P: (847) 517-7225 | F: (847) 517-7229 Sujata Sarkar, MD Kaleo Ede, MD (Program Chair) University of Arizona Phoenix, AZ Associate Director Tucson, AZ Danielle Carrier Theresa Frimel, FNP-C Treasurer Scottsdale, AZ Deborah J. Power, DO, MS Tucson, AZ Eric A. Peters, MD Arizona Arthritis Rheumatology Associate Vice Chair Phoenix, AZ Amer Al-khoudari, MD Wake Forest Baptist Medical Center Deborah J. Power, DO, MS Chandler, AZ Tucson, AZ

Members At Large Sheetal K. Chhaya, DO Maricopa Medical Center Paradise Valley, AZ

Eric A. Peters, MD Arizona Arthritis Rheumatology Associate Phoenix, AZ

AURA 2018 FACULTY MEMBERS Randy Q. Cron, MD, PhD Madelaine A. Feldman, MD, FACR Daniele Piomelli, PhD, MD (hc) University of Alabama At Birmingham The Rheumatology Group University of California, Irvine Children’s of Alabama New Orleans, LA Irvine, CA Birmingham, AL Polly J. Ferguson, MD Dominick G. Sudano, MD Jeffrey R. Curtis, MD, MS, MPH University of Iowa Hosps/Clinics University of Arizona Tucson Univ of Alabama-Birmingham Iowa City, IA Tucson, AZ Birmingham, AL Chester V. Oddis, MD Daniel J. Wallace, MD, FACP, MACR Kaleo Ede, MD University of Pittsburgh David Geffen School of Medicinwe At UCLA Phoenix, AZ Pittsburgh, PA Beverly Hills, CA

Arizona United Rheumatology Alliance 2018 Annual Meeting TABLE OF CONTENTS

2018 Arizona United Rheumatology Alliance Annual Meeting June 1 – 3, 2018 Welcome Messages ...... Inside Front Cover

AURA 2017-2018 Board of Directors & Faculty...... Inside Front Cover

General Meeting Information ...... 1

CME Information ...... 2

Program Schedule ...... 4

Biosketches ...... 5

Industry Satellite Symposium Events ...... 9

Industry Support ...... 10

Exhibit Hall Floor Plan ...... 12

GENERAL MEETING INFORMATION

Registration/Information Desk Hours Welcome Reception with Exhibitors Location: Anasazi Foyer Location: Anasazi Ballroom

Friday, June 1, 2018 5:00 p.m. – 8:30 p.m. Friday, June 1, 2018 7:00 p.m. – 8:30 p.m. Saturday, June 2, 2018 6:30 a.m. – 1:00 p.m. Sunday, June 3, 2018 6:30 a.m. – 12:00 p.m. Meet with colleagues and visit exhibits while enjoying cocktails and hors d’oeuvres.

Exhibit Hall Hours Location: Anasazi Ballroom Annual Dinner Location: Agave Ballroom Friday, June 1, 2018 7:00 p.m. – 8:30 p.m. Saturday, June 2, 2018 7:30 a.m. – 10:30 a.m. Saturday, June 2, 2018 6:00 p.m. – 7:30 p.m. Sunday, June 3, 2018 7:30 a.m. – 10:30 a.m. Join your colleagues at the Annual Dinner! Enjoy an evening of food and conversation with your fellow attendees and their families. This event is limited to physicians, non-physician providers, and their Industry Satellite Symposium Events families. Please see the registration desk for more information. Location: Ocotillo Ballroom

Saturday, June 2, 2018 Breakfast 7:00 a.m. – 8:00 a.m. Lunch 11:45 a.m. – 12:45 p.m. Sunday, June 3, 2018 Breakfast 7:00 a.m. – 8:00 a.m.

Arizona United Rheumatology Alliance 2018 Annual Meeting 1 CME INFORMATION

EDUCATIONAL NEEDS EDUCATIONAL OBJECTIVES

The idiopathic inflammatory myopathies (IIM) are a rare and At the conclusion of the AURA 2018 Annual Meeting, attendees heterogeneous group of multisystem autoimmune diseases. will be able to: Understanding the expanding field of autoantibodies associated 1. Review the clinical features of myositis classification as it with these diseases is paramount to framing the pathophysiology, relates to myositis-associated autoantibodies. clinical symptoms, prognosis and management of patients. 2. Explain the spectrum of selected autoantibodies seen in patients with myositis and their clinical associations. The use of biologic therapeutic agents for the treatment of 3. Discuss selected treatment aspects of myositis and rheumatic diseases has been associated with the development autoimmune ILD. of disseminated coccidioidomycosis infections. A complete 4. Review the risk of coccidioidomycosis infection in the understanding of proposed screening guidelines and the ongoing rheumatic population. management of those with rheumatic diseases in the setting of 5. Review screening habits and how they relate to the 2016 coccidioidomycosis infection in Arizona is central to ensuring the IDSA guidelines for patients with coccidioidomycosis safety of our patients. infection. 6. Discuss research since 2016 relating to screening and Autoinflammatory bone disorders are an emerging group of treatment of patients with coccidioidomycosis infection. diseases primarily affecting children but also seen in adults. 7. Identify the treatment and management of infected Understanding the clinical presentation, scope of disease, and patients with coccidioidomycosis. management strategies are key for rheumatologists to aide in the 8. Describe the clinical presentation of auotinflammatory care of these patients. bone disorders. 9. Learn what disorders are associated with sterile Cannabis is quickly becoming a more accessible option for patients osteomyelitis. with a wide range of medical conditions, including rheumatic 10. Describe the current genetic syndromes that have sterile diseases. Understanding the pharmacological effects as well as osteomyelitis/osteitis as a phenotype. the potential risks and benefits of cannabis-based therapies are 11. Define how cannabis produces its pharmacological important for rheumatologists and allied health professionals to effects in the body (role and localization of cannabinoid aide in the care of our patients. receptors). 12. Identify the primary components and functions of the Rheumatology and other medical fields have embraced a new endogenous cannabinoid system. form of research studies in recent years known as “real-world 13. Discuss potential benefits and risks of cannabis-based evidence” or “big data.” This includes data mining from electronic medicines, especially as it pertains to the field of health records, claims and billing data, and disease registries. rheumatology. Understanding the role of this data collection and how it relates 14. Define the role of real-world data and health informatics to clinical care and research in rheumatology is key for practicing to support clinical care and research. rheumatologists and allied health professionals. 15. Compare & contrast strengths and limitations of various healthcare-related data sources, tools, and approaches Despite the apparent slower progress of development of to working with digital information. newer treatment strategies for patients with Systemic Lupus 16. Discuss the current state of clinical trials for lupus and Erythematosus compared with other rheumatic diseases, there which agents are now in the pipeline. has been considerable improvements made through clinical 17. Review the use of metrics and measurements in and translational research studies over the last ten years. It is assessing lupus activity. important for rheumatologists to review the emerging identified 18. Review when to consider using biologics and targeted targets including B-cells, interleukins, interferon alpha, and T-cells, therapies that are currently available to treat lupus as well as how to choose the appropriate treatment given patient patients. specific factors. 19. Describe the challenges and opportunities related to data linkages and integration of digital data into traditional Macrophage activation syndrome (MAS) is an acute overwhelming health care & research settings across a variety of inflammatory response that is known to complicate multiple different rheumatology use cases. rheumatic diseases. There have been several important advances 20. Recognize the common infectious triggers of MAS. in the understanding of the pathophysiology of this syndrome 21. Discuss the genetic predispositions for developing MAS. over the past few years. Early recognition of the condition has 22. Discuss treatment strategies for MAS. recently been aided by the development of classification criteria 23. Explain what a pharmacy benefit manager (PBM) does. for patients with MAS complicating systemic Juvenile Idiopathic 24. Describe what the rebate system is and how it affects Arthritis. While corticosteroids and other immunosuppressives are formularies for PBMs. the mainstay of treatment, some targeted biologic anti-cytokine 25. Identify what step edits and nonmedical switching are therapy have been successfully used as well. and how they are a result of the rebate system.

Arizona United Rheumatology Alliance 2018 Annual Meeting 2 CME INFORMATION

CONTINUING MEDICAL EDUCATION CREDIT INFORMATION

Accreditation This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Surgeons and the Arizona United Rheumatology Alliance. The American College of Surgeons is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™ The American College of Surgeons designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Non-physician healthcare professionals will receive a Certificate of Attendance. For information on the applicability and acceptance of Certificates of Attendance for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.

General Disclaimer: The statements and opinions contained in this program are solely those of the individual authors and contributors and not of the Arizona United Rheumatology Alliance. The appearance of the advertisements is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. The content of this publication may contain discussion of off-label uses of some of the agents mentioned. Please consult the prescribing information for full disclosure of approved uses. The Arizona United Rheumatology Alliance disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the abstracts or advertisements.

Disclosure Information In compliance with the ACCME Accreditation Criteria, the American College of Surgeons, as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. All reported conflicts are managed by a designated official to ensure a bias-free presentation.

The disclosure report for this meeting can be found in the course materials provided to you at registration.

Special Assistance: We encourage participation by all individuals. If you have a disability, advance notification of any special needs will help us better serve you. Call (847) 517-7225 if you require special assistance to fully participate in the meeting.

Arizona United Rheumatology Alliance 2018 Annual Meeting 3 PROGRAM SCHEDULE

All sessions will be located in Agave Ballroom unless otherwise noted. Speakers and times are subject to change.

FRIDAY, JUNE 01, 2018 SUNDAY, JUNE 03, 2018

OVERVIEW OVERVIEW

5:00 p.m. - 8:30 p.m. Registration/Information Desk Open 6:30 a.m. - 12:00 p.m. Registration/Information Desk Open Location: Anasazi Foyer Location: Anasazi Foyer

7:00 p.m. - 8:30 p.m. Welcome Reception with Exhibitors 7:30 a.m. - 10:30 a.m. Exhibit Hall Open Location: Anasazi Ballroom Location: Anasazi Ballroom

SATURDAY, JUNE 02, 2018 GENERAL SESSION

OVERVIEW 7:00 a.m. - 8:00 a.m. Industry Satellite Symposium Breakfast 6:30 a.m. - 1:00 p.m. Registration/Information Desk Open Location: Ocotillo Ballroom Location: Anasazi Foyer 8:00 a.m. - 8:15 a.m. Welcome and Opening Remarks President: Kaleo Ede, MD 7:30 a.m. - 10:30 a.m. Exhibit Hall Open Location: Anasazi Ballroom 8:15 a.m. - 9:00 a.m. Big Data in Rheumatology: Who Needs It? Speaker: Jeffrey R. Curtis, MD, MS, GENERAL SESSION MPH

7:00 a.m. - 8:00 a.m. Industry Satellite Symposium 9:00 a.m. - 9:45 a.m. New Treatments for Lupus Breakfast Speaker: Daniel J. Wallace, MD, FACP, Location: Ocotillo Ballroom MACR

8:00 a.m. - 8:15 a.m. Welcome and Opening Remarks 9:45 a.m. - 10:15 a.m. Break in the Exhibit Hall President: Kaleo Ede, MD Location: Anasazi Ballroom

8:15 a.m. - 9:00 a.m. Myositis and Autoimmune ILD 10:15 a.m. - 11:00 a.m. “Macrophage Activation Syndrome Speaker: Chester V. Oddis, MD – Kill or Be Killed” Speaker: Randy Q. Cron, MD, PhD 9:00 a.m. - 9:45 a.m. Drug Pricing: The Most Important Player you Never Knew Existed 11:00 a.m. - 11:45 a.m. Management of Coccidioidomycosis Speaker: Madelaine A. Feldman, MD, in Rheumatic Patients on Biologic FACR Response Modifiers Speaker: Dominick G. Sudano, MD 9:45 a.m. - 10:15 a.m. Break in the Exhibit Hall Location: Anasazi Ballroom 11:45 a.m. - 12:00 p.m. AURA Annual Business Meeting President: Kaleo Ede, MD 10:15 a.m. - 11:00 a.m. Autoinflammatory Bone Disease Speaker: Polly J. Ferguson, MD

11:00 a.m. - 11:45 a.m. Health Impact of Cannabis - A Primer Speaker: Daniele Piomelli, PhD, MD (hc)

11:45 a.m. - 12:45 p.m. Industry Satellite Symposium Lunch Location: Ocotillo Ballroom

6:00 p.m. - 7:30 p.m. Annual Dinner

Arizona United Rheumatology Alliance 2018 Annual Meeting 4 BIOSKETCHES

Randy Q. Cron, MD, PhD multiple, pooled national data sources. He is the Co-PI of the Dr. Cron is a basic, translational, and clinical scientist who studies PCORI-funded Patient Powered Research Network “Arthritis- macrophage activation syndrome. Dr. Cron received his MD from Power” registry, focused on RA, psoriasis, and psoriatic arthritis. UCLA, and completed his pediatric residency at Stanford, and He also leads the multi-center NIH-funded large pragmatic pediatric rheumatology fellowship at the University of Washington. randomized controlled trial “VERVE” studying the safety and After completing his post-doctoral training at Stanford, Dr. Cron effectiveness of the live herpes zoster vaccine in patients receiving held his first faculty appointment at the University of Pennsylvania/ biologic agents. He is a member of the Center for Disease Control Children’s Hospital of Philadelphia until being recruited in 2007 to (CDC) Advisory Committee on Immunization Practices (ACIP) the University of Alabama at Birmingham (UAB) to start a Pediatric Herpes Zoster workgroup. In 2015, he was appointed as a member Rheumatology Division. Professor Cron serves as the Arthritis to the FDA Arthritis Advisory Committee. Foundation, Alabama Chapter Endowed Chair, and Division Dr. Curtis also studies risk factors for and outcomes of Director of Pediatric Rheumatology at UAB. He also developed osteoporosis. He was a member of the ACR’s task force to update and serves as the Program Director of the Pediatric Rheumatology recommendations for the management of glucocorticoid induced Fellowship Program at UAB. He has grown his division from zero osteoporosis (GIOP). He served on the ASBMR Task Force on to 6 physician-scientists and 3 pediatric nurse practitioners, the Atypical Subtrochanteric and Diaphyseal Fractures. largest Pediatric Rheumatology program in the Southeastern United States. Dr. Cron also has a PhD in Immunology from the Dr. Curtis is a member of the American College of Rheumatology University of Chicago, and his laboratory’s basic research focuses (ACR), the International Society for Pharmacoepidemiology on transcriptional regulation in CD4 T lymphocytes as it relates (ISPE), the American Medical Informatics Association (AMIA), and to both systemic lupus erythematosus (SLE) and HIV-1/AIDS. the American Society of Bone and Mineral Research (ASBMR). His clinical and translational research interests include childhood He has been on the editorial board for Arthritis & Rheumatism, arthritis related macrophage activation syndrome (MAS) and Pharmacoepidemiology and Drug Safety (PDS) and Arthritis Care temporomandibular joint (TMJ) arthritis, for both of which he is and Research (AC&R). He has authored more than 400 peer- known world-wide. reviewed manuscripts, review articles and book chapters.

Jeffrey R. Curtis, MD, MS, MPH Kaleo Ede, MD Dr. Jeffrey Curtis is a Professor of Medicine in the Division of Clinical Dr. Ede is currently presiding as the Chairman of the Board for Immunology and Rheumatology at the University of Alabama at AURA in his first year. He is a Clinical Assistant Professor of Birmingham (UAB). Dr. Curtis received a Medical Degree (MD) Pediatrics at the University of Arizona, College of Medicine and a Master of Public Health (MPH) degree from Oregon Health & Phoenix, as well as an active member of the Division of Pediatric Sciences University in Portland, OR. He subsequently completed Rheumatology at Phoenix Children’s Hospital for the last ten years. a residency in internal medicine at Oregon Health & Science Dr. Ede received his Medical Degree (MD) from the University of University and a fellowship in rheumatology at UAB. He completed Hawaii, John A. Burns School of Medicine in Honolulu, Hawaii. a graduate program in Clinical Informatics at Stanford University He subsequently completed a combined residency in internal and received his Master of Science (MS) degree in epidemiology medicine and pediatrics at Banner University Medical Center and at the Harvard School of Public Health. He is board certified in Phoenix Children’s Hospital. He finished his fellowship in pediatric both rheumatology and clinical informatics. rheumatology at the University of California, Los Angeles. He is board certified in pediatric rheumatology. Dr. Curtis currently holds the Harbert-Ball Endowed Professorship in Rheumatology and Immunology at UAB. He is the Co-Director of the UAB Center for Education and Research on Therapeutics Madelaine A. Feldman, MD, FACR Dr. Feldman is the founding member and Past President of (CERTs) of Musculoskeletal Disorders, which has a major the Rheumatology Alliance of Louisiana, Vice-President of the emphasis on evaluating the safety and comparative effectiveness Coalition of State Rheumatology Organizations, (CSRO), Board of medications for rheumatic diseases. Additionally, as the Director Liaison to the Association of Women in Rheumatology, and of the UAB Arthritis Clinical Intervention Program, he leads the recently served on the Insurance Subcommittee for the ACR. She clinical trials unit for the rheumatology division at UAB, with a is the Chair of the Alliance for Safe Biologic Medicines. She is particular focus on rheumatoid arthritis (RA) and psoriatic arthritis also a member of the Biologic Working Group for the Alliance for (PsA). He is the Co-Director of the UAB Pharmacoepidemiology Patient Access. She is a Clinical Associate Professor of Medicine and Pharmacoeconomics Research (PEER) Unit. In 2012, he at Tulane University School of Medicine, and has been named one was awarded the Henry Kunkel Young Investigator Award by the of the Top Doctors in New Orleans for over 10 years. She was American College of Rheumatology (ACR) and was accepted into awarded the Distinguished Service Award this year by the Tulane the American Society for Clinical Investigation (ASCI) in 2016. Medical Alumni association and named one of the 2017 top 50 The evaluation of the efficacy, comparative effectiveness, and women in New Orleans by New Orleans City Business. safety of the medications used to treat rheumatoid arthritis and spondyloarthritis are among Dr. Curtis’s research interests. He Polly J. Ferguson, MD served on the Core Expert Panel for the ACR’s 2008, 2012, and Dr. Ferguson is a Professor of Pediatrics and Director of Pediatric 2015 Recommendations for the Use of Nonbiologic and Biologic Rheumatology at the University of Iowa Carver College of Disease Modifying Antirheumatic Drugs in RA. He was the Deputy Medicine. She runs an NIH funded research program aimed at Director for a collaborative project between the FDA, the Agency better understanding the pathogenesis of autoinflammatory bone for Healthcare Research and Quality (AHRQ), and a number of disorders. academic centers studying the safety of biologic agents using

Arizona United Rheumatology Alliance 2018 Annual Meeting 5 b BIOSKETCHES

Chester V. Oddis, MD State University in 2001 and his Medical Doctorate from Drexel Dr. Oddis has been Professor of Medicine in the Division of University College of Medicine in 2008. He completed his internal Rheumatology and Clinical Immunology since 2001 and Director medicine residency at the University of Arizona in 2012. of the Myositis Center at the University of Pittsburgh since 2010. His major research interest is the diagnosis and management of He has devoted most of his career to the investigation and coccidioidomycoses in patients with rheumatic diseases. He also treatment of inflammatory myopathy. He has conducted research runs the Clinical Research Unit at the Arizona Arthritis Center, and on the epidemiology, clinical features, autoantibody associations, Rheumatology Interest Group at the University of Arizona, which pathogenesis, and treatment of myositis. He has authored or promotes and mentors research in rheumatology for residents and co-authored over 170 peer-reviewed and invited publications, fellows. He is the Assistant Program Director for the University of most of them related to inflammatory muscle disease and its co- Arizona Rheumatology Fellowship Program, and is involved in morbidities. As Director of the Myositis Center at the University teaching for rheumatology fellows, internal medicine residents and of Pittsburgh, he supervises and manages a clinically - and medical students. serologically - defined, longitudinal myositis registry of over 1,000 patients with adult polymyositis, adult dermatomyositis, and overlap myositis disorders. He served as principal investigator Daniel J. Wallace, MD, FACP, MACR Dr. Wallace has authored nearly 400 peer reviewed manuscripts, of an NIH-funded multicenter clinical trial of rituximab in the 25 book chapters, eight textbooks (on lupus, osteoarthritis, treatment of myositis, the largest trial ever completed for this Sjogren’s syndrome and fibromyalgia) and his practice includes disease. He has contributed significantly to characterizing the caring for 2,000 lupus patients, the largest lupus cohort in the pulmonary manifestations of inflammatory myopathy, particularly United States. Dr Wallace is co-chair of the Lupus Industry interstitial lung disease, and he has served on a number of Council of the Lupus Research Alliance, past chair of the Lupus panels for developing clinical trial guidelines for both myositis Foundation of America, and has served on the Board of Directors and autoimmune interstitial lung disease. He and his colleagues of the United Scleroderma Foundation and the Medical Advisory developed the web-based Rheumatic Disease Data Management Board of the Sjogren’s Syndrome Foundation. He has been Chief System, which enables myositis investigators to link disease of Rheumatology at the City of Hope and Cedars-Sinai Medical activity and damage measures with clinical, laboratory, serologic Center, and chairman of the Research and Education Foundation and experimental data over time. His current research is funded by of the Am erican College of Rheumatology. NIH, private sources and industry. He is currently participating in a large number of national and international collaborations, including Dr. Wallace is the recipient of the Lupus Foundation of America several multicenter clinical trials for the therapy of myositis. Humanitarian Award, Achievement Award of the Lupus Research Institute, Spirit Award of the Scleroderma Foundation, the Jane Daniele Piomelli, PhD, MD (hc) Wyman Humanitarian Award from the Arthritis Foundation, and Dr. Piomelli studied pharmacology and neuroscience with James the Healthcare Professional Leadership Award from the Sjogren’s H. Schwartz and Eric Kandel at Columbia University (1983-1988), Syndrome Foundation. and with Paul Greengard at the Rockefeller University (1988- 1990). In 2000, two of his mentors (Kandel and Greengard) were While a fellow at UCLA, Dr. Wallace conducted pioneering arthritis awarded the Nobel Prize for their contributions to physiology research and developed a close relationship with his mentor, and medicine. After working at the INSERM in Paris, France, Edmund Dubois. Dr. Dubois had the largest lupus practice in the and at the Neurosciences Institute in San Diego, California, with United States at the time and was the principal editor of the only Nobel Laureate Gerald Edelman, Daniele joined the University lupus textbook. He assumed Dr. Dubois’ practice upon his passing of California, Irvine, where he is now Louise Turner Arnold Chair in 1985. Dr. Wallace is the author of eight medical textbooks in Neurosciences and Professor of Anatomy and Neurobiology, (including the last six editions of Dubois’ Lupus Erythematosus, Pharmacology and Biological Chemistry. Daniele is an author of All About Fibromyalgia, The Lupus Book, All About Osteoarthritis, more than 400 peer-reviewed articles in journals such as Nature, The New Sjogren’s Syndrome Handbook, and Fibromyalgia & Science, Nature Medicine, PNAS and Nature Neuroscience, three Other Central Pain Syndromes). In addition, his work can be found full-length books, and 34 patents. He co-founded the department in 25 book chapters and over 375 medical publications which of drug discovery and development (D3) at the Italian Institute of have appeared in the New England Journal of Medicine, Annals Technology in Genoa, Italy, which he directed from 2007 to 2016, of Internal Medicine, the Lancet, Journal of Clinical Investigation, and the biopharmaceutical start-ups Kadmus Pharmaceuticals, Journal of Immunology and Journal of the American Medical NeoKera Pharmaceutical and Aspire Biosciences, all based on Association. discoveries made in his lab. He is Editor-in-Chief of Cannabis and Dr. Wallace has been recognized as among the 200 best doctors Cannabinoid Research, the only peer-reviewed journal entirely in the nation by Town and Country Magazine, and among the best dedicated to the study of cannabis, its derivatives, and their doctors in Los Angeles by Los Angeles Magazine, Best Doctors endogenous counterparts in the human body. in America editions since 1994. Dr. Wallace spends 20 percent of his time teaching and in clinics where he provides free medical Dominick G. Sudano, MD care. His efforts have raised over $20 million for various rheumatic Dr. Sudano is an Assistant Professor and a practicing rheumatologist disease organizations. at the University of Arizona. He is board certified by the American Board of Internal Medicine in both general internal medicine and rheumatology. He completed his rheumatology fellowship at the University of Arizona in 2014. He earned his Bachelor’s Degree in biochemistry and molecular biology at Pennsylvania

Arizona United Rheumatology Alliance 2018 Annual Meeting 6 COME FOR THE DATA STAY FOR THE RESULTS MEET TALTZ AT BOOTH LOCATION

Learn about the Taltz Savings Card Program at taltz.com/hcp

If you are a US medical doctor with an active state license number, the value of the food, beverage, and/or educational item that you receive when attending this program may be disclosed on Eli Lilly and Company’s Physician Payment Registry and/or the National Physician Payment Transparency Program (NPPTP) Open Payments report under the federal Sunshine Act as a transfer of value made to you by Lilly. As a result of enacted state regulations, food and beverages will not be provided to healthcare professionals licensed in the states of Minnesota, Massachusetts, and Vermont. Additionally, educational items will not be provided to healthcare professionals licensed in Minnesota. Federal Veterans Affairs (VA) regulations and several states also prohibit state/government employees from receiving or being provided gift items, which may include educational materials and meals. Please consult your state regulations and ethics laws to see if such prohibition would apply to you. This medical presentation is intended only for invited healthcare professionals for whom the information to be presented is relevant to their practice. We regret that spouses or other guests cannot be accommodated. This is a promotional program and no continuing medical education (CME) credits are offered.

Visit our booth

Sanoﬁ Genzyme and Regeneron are committed to providing resources to better understand the pathogenesis of rheumatoid arthritis and to research the unmet needs of patients with this disease.

SAUS.SARI.17.10.7778_R01_SSAU_GenericCongressAd.indd 2 4/13/18 1:41 PM INDUSTRY SUPPORT

INDUSTRY SATELLITE SYMPOSIUM EVENTS SATURDAY, JUNE 2, 2018 SUNDAY, JUNE 3, 2018 7:00 a.m. - 8:00 a.m. 7:00 a.m. - 8:00 a.m.

Industry Satellite Symposium Breakfast Industry Satellite Symposium Breakfast Location: Ocotillo Ballroom Location: Ocotillo Ballroom Sponsored by: Lilly Sponsored by: Sanofi Genzyme Regeneron

“CYTOKINE SIGNALING AND THE JAK-STAT PATHWAY: “A NEW TREATMENT OPTION FOR ADULT PATIENTS ROLE IN RHEUMATOID ARTHRITIS (RA)” WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS” John Tesser, MD Alvin Wells, MD, PhD 11:45 a.m. - 12:45 p.m.

Industry Satellite Symposium Lunch Location: Ocotillo Ballroom Sponsored by: Bristol-Myers Squibb

“PATHOGENESIS OF BONE EROSIONS IN RA”

John Tesser, MD

Exhibit Guide Arizona United Rheumatology Alliance 2018 Annual Meeting 9 INDUSTRY SUPPORT

THANK YOU TO OUR 2018 CONTRIBUTOR Bristol-Myers Squibb THANK YOU TO OUR 2018 EXHIBITORS AbbVie Lilly Actelion Mallinckrodt Pharmaceuticals Amgen, Inc. McKesson Specialty Health Antares Pharma Medac Pharma, Inc. Arthritis Foundation Novartis Bristol-Myers Squibb Pfizer, Inc. Celgene Corporation Primus Pharmaceuticals, Inc. Exagen Diagnostics, Inc. Radius Health Flexion Therapeutics Rheumatology Nurses Society Genentech Sanofi Genzyme Regeneron GlaxoSmithKline Sobi, Inc. Horizon Pharma, Inc. TSI Healthcare Janssen Biotech, Inc. UCB, Inc.

At Bristol-Myers Squibb, we are working together for patients Our mission is clear — we discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our sense of urgency is real — we work every day to push the boundaries of scientific discovery and to make a meaningful difference in the lives of patients. It’s what we do. It’s why we do it.

Bristol-Myers Squibb is proud to support the 2018 Arizona United Rheumatology Alliance

bms.com

Exhibit Guide Arizona United Rheumatology Alliance 2018 Annual Meeting 10 Creating a world free from immune diseases. That’s our vision.

At Janssen, we like to dream big. And our hope for immune and inﬂammatory diseases is no exception. Through science and collaboration, we look to transform how diseases like rheumatoid arthritis, Crohn’s disease and plaque psoriasis are treated today—and prevented tomorrow. We dream of a future free of the pain and challenges for the approximately one in 10 people worldwide living with these diseases. We are relentless in our pursuit to advance science and deliver breakthrough medicines to make a diﬀerence in people’s lives. But bringing forward new solutions isn’t enough. We want to shorten the journey from diagnosis to treatment. And through our education and access programs, we’re here to help forge that path. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com

J&J Healthcare Systems, Inc. ©JJHCS 2018 The image depicted contains models and is being used for illustrative purposes only.

Exhibit Guide Arizona United Rheumatology Alliance 2018 Annual Meeting 11 b EXHIBIT HALL FLOOR PLAN

7 8 9 10 11 12 13 14

6 15

5 25 26 16

4 24 27 17

3 23 28 18

2 22 29 19

1 21 ENTER

Company Name Table # Company Name Table # AbbVie 24 Lilly 15 Actelion 4 Lilly 22 Amgen 28 Mallinckrodt Pharmaceuticals 12 Amgen 29 McKesson Specialty Health 21 Antares Pharma 13 Medac Pharma 6 Bristol-Myers Squibb 2 Novartis 9 Celgene 1 Pfizer 25 Exagen Diagnostics 18 Primus Pharmaceuticals 17 Flexion Therapeutics 20 Radius Health 26 Genentech 27 Sanofi Genzyme Regeneron 23 GlaxoSmithKline 7 SOBI, Inc. 11 GlaxoSmithKline 8 TSI Healthcare 19 Horizon Pharma 3 UCB, Inc 10 Janssen Biotech 5

Exhibit Guide Arizona United Rheumatology Alliance 2018 Annual Meeting 12

THANK YOU TO OUR 2018 PROMOTIONAL PARTNERS

PLATINUM LEVEL PARTNERS

GOLD LEVEL PARTNERS

SILVER LEVEL PARTNERS